Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 October 2024
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2025
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Renal cell carcinoma Pathways Pilot [ID6186]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC